Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year

GOTHENBURG, Sweden, Jan. 27, 2026 /PRNewswire/ -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge.

Higher demand for consumables for ECLS-therapy in the quarter and in Acute Care Therapies contributed to Getinge's performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general, sales are more volatile between quarters for Life Science, which grew organically for the full-year despite the weaker end.

"Despite headwinds from tariffs and currency effects for the full-year 2025 of more than SEK 1 billion compared with last year, we maintained adjusted EBITA margin for the full-year in line with 2024 and deliver a solid cash flow. Excluding effects from currency and tariffs, adjusted EBITA margin was 20.3% in the quarter and 16.0% for the full year, which is considerably higher than last year. This confirms the positive trend in underlying profitability thanks to our sustained focus on price adjustments, productivity and cost control," says Mattias Perjos, President & CEO at Getinge.

Getinge's intensive development efforts have resulted in several important product launches during the quarter.

"One example is Automatiq, the next generation of sterile reprocessing automation systems using smart robotics, which will ultimately lead to safer and more efficient processes. The system is requested by customers, and we have already received the first orders. The ambition is to accelerate development efforts of new products over the coming years which will further strengthen our competitiveness," says Perjos.

Getinge continued to make progress in regulatory compliance. Rotaflow consumables in ECLS received EU MDR approval and the ...